News
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback